Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 243

Results For "AI"

8450 News Found

Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
Drug Approval | April 17, 2025

Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg

Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA


Lupin receives EIR from USFDA for its injectable facility in Nagpur
Drug Approval | April 17, 2025

Lupin receives EIR from USFDA for its injectable facility in Nagpur

The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024


Fortis Healthcare launches Fortis Institute of Genomic Medicine
News | April 17, 2025

Fortis Healthcare launches Fortis Institute of Genomic Medicine

Genomics is transforming the future of modern medicine and treatment modalities across specialties


Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Sustainability | April 17, 2025

Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets

Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger


Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery
News | April 17, 2025

Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities


Ami Organics to change name as Acutaas Chemicals
News | April 16, 2025

Ami Organics to change name as Acutaas Chemicals

This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,


AstraZeneca Pharma India surrenders marketing authorisation for Olaparib 100mg and 150mg
News | April 16, 2025

AstraZeneca Pharma India surrenders marketing authorisation for Olaparib 100mg and 150mg

The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons


Lonza joins CMAC to enhance service offering for specialty, enhanced drug product and particle technologies
News | April 15, 2025

Lonza joins CMAC to enhance service offering for specialty, enhanced drug product and particle technologies

Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches


Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis
Clinical Trials | April 15, 2025

Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis

More than 40 types of Amyloid proteins are discovered till date


Biocon Biologics secures market entry date for Yesafili in US
News | April 15, 2025

Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions